NVSTEnvista Holdings Corporation
Is the price fair?
Neither cheap nor expensive: nothing decisive, though cheap vs its sector.
Priced for ~2% a year FCF growth. Roughly in line with its three-year revenue growth of 3% a year.
In its normal range: P/E 40.7 vs a 27.6 median over 21 quarters (+48% vs median).
Sector median 25.1× across 135 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
Unless marked, from derived, as of Jul 3, 2026.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What NVST's price assumes
Envista Holdings Corporation trades at 40.7× earnings against 40.7× for the median Medical Instruments & Supplies name, cheaper than its own group.
Trailing P/E · Medical Instruments & Supplies median 40.7 · cheaper than the typical name in its group
- Price / sales
- 1.33
Price / sales · today's price, trailing year to Jul 3, 2026
- Free cash flow yield
- 6.6%
Free cash flow yield · Medical Instruments & Supplies median 3.6%
- Growth the price implies
- +2.1%
Growth the price implies · The price pays for +2.1% free cash flow growth a year for a decade; the business has delivered +16% a year over the last three.
Details›
- Price / booktoday's price, trailing year to Jul 3, 2026
- 1.23
- EV / EBITtoday's price, trailing year to Jul 3, 2026
- 15.0
- EV / salestoday's price, trailing year to Jul 3, 2026
- 1.44
- Healthcare median P/E503 names
- 27.9
- Medical Instruments & Supplies median P/E32 names
- 40.7
- Free cash flow, trailing twelve months
- $248M
- Market capitalisation160.6 million shares, counted Jul 31, 2026
- $3.79B
- 3-year revenue growth
- +3.4%
- 3-year free cash flow growth
- +16%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $14.97 |
| Its own P/E history, median | $15.99 |
| Its own P/E history, upper quartile | $32.89 |
| 52-week range | $18.95 – $30.26 |
| Today | $23.59 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
What is it worth?
Today's price against what its own multiples, its cash flow and your growth assumption say it is worth.
Against its own past
Its multiples now against their own history, and how much of the price move came from earnings rather than the multiple.
Medical Instruments & Supplies
Ranks #7 of 20 by RyuScore